About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Search This Discipline
Journals
High Impact Journals
Most Cited Journals
Most Published Journals
Authors
Most Cited Authors
Most Published Authors
Affiliations
Top Institutions
Top Schools
exaly
›
Disciplines
›
Hematology
›
Top Articles
Hematology
148
Journals
668.9K
Articles
12.3M
Citations
108.5K
Authors
Most Cited Articles of Hematology in 2022
Title
Journal
Year
Citations
Cancer statistics, 2022.
Ca-A Cancer Journal for Clinicians
2022
842
Cancer statistics for African American/Black People 2022.
Ca-A Cancer Journal for Clinicians
2022
17
Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
Journal of Hematology and Oncology
2022
16
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Annals of Oncology
2022
15
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Leukemia
2022
15
MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME.
Blood
2022
14
The long and short non-coding RNAs modulating EZH2 signaling in cancer.
Journal of Hematology and Oncology
2022
12
Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management.
American Journal of Hematology
2022
12
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
Annals of Oncology
2022
11
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Haematology,the
2022
11
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
Annals of Oncology
2022
10
Vasculopathy in COVID-19.
Blood
2022
10
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
Blood Cancer Discovery
2022
10
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Annals of Oncology
2022
10
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
2022
10
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Annals of Oncology
2022
10
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial.
Haematologica
2022
9
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Annals of Oncology
2022
9
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Lancet Haematology,the
2022
9
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.
Annals of Oncology
2022
9
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Journal of Hematology and Oncology
2022
9
European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
Annals of Oncology
2022
8
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Blood Advances
2022
8
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Journal of Hematology and Oncology
2022
8
Clinical management of metastatic colorectal cancer in the era of precision medicine.
Ca-A Cancer Journal for Clinicians
2022
8
site/software ©
exaly
; All materials licenced under
CC by-SA
.